Emergent Biosolutions (NYSE:EBS) Posts Earnings Results, Beats Estimates By $0.46 EPS

Emergent Biosolutions (NYSE:EBS) announced its earnings results on Thursday. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.46, FiscalAI reports. Emergent Biosolutions had a positive return on equity of 10.64% and a negative net margin of 1.27%.The firm had revenue of $156.10 million for the quarter, compared to analyst estimates of $145.00 million.

Here are the key takeaways from Emergent Biosolutions’ conference call:

• Emergent reported Q1 revenue of $156 million (above the high end of guidance) and an Adjusted EBITDA of $36 million with a 23% margin, while cash and liquidity improved to $160M and $260M respectively and net debt fell ~22% year‑over‑year.
• The April 2026 debt refinancing extended maturities (out to 2031), lowered interest costs, added a $75M delayed‑draw term loan and a $50M revolver, which management says enhances liquidity and financial flexibility for growth.
• Management emphasized growth levers including international MCM expansion (internationals were ~37% of MCM revenue in Q1), new NARCAN line extensions (carrying case and multi‑pack), strategic manufacturing partnerships (Substipharm, SAB) and continued business‑development/acquisition activity.
• Emergent expects a $50.4 million cash outflow in Q2 as an accrued acquisition obligation to Ridgeback related to the Ebanga/BARDA contract, which management has recorded as a current liability.

Emergent Biosolutions Trading Up 3.0%

Shares of NYSE EBS traded up $0.25 during trading on Friday, hitting $8.48. 1,407,261 shares of the company were exchanged, compared to its average volume of 558,687. Emergent Biosolutions has a 12-month low of $4.71 and a 12-month high of $14.06. The company has a debt-to-equity ratio of 1.09, a quick ratio of 2.41 and a current ratio of 5.01. The company has a fifty day moving average price of $8.54 and a 200-day moving average price of $10.29. The firm has a market capitalization of $437.96 million, a PE ratio of 10.10 and a beta of 2.33.

Trending Headlines about Emergent Biosolutions

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: Q1 earnings beat and stronger margins — Emergent reported $0.21 EPS vs. a consensus loss and revenue of $156.1M above estimates; management highlighted improving profitability and returned a positive ROE. The better‑than‑expected quarter and upbeat commentary are the primary drivers of the stock move today. Earnings Press Release
• Positive Sentiment: Regulatory win expands market for ACAM2000 — Singapore’s HSA approved an expanded indication for ACAM2000 to include prevention of mpox in high‑risk adults, which supports incremental product sales outside the U.S. and validates market access progress. Singapore Approval
• Positive Sentiment: Earnings call emphasized “turnaround momentum” — Management highlighted cost discipline, margin recovery and business mix improvement on the call, reinforcing investor expectations for continued operational improvement. Earnings Call Highlights
• Neutral Sentiment: Board and incentive plan changes approved — Shareholders backed board/incentive adjustments at the annual meeting, reducing governance uncertainty but with limited immediate financial impact. This supports corporate stability. Shareholder Vote
• Neutral Sentiment: FY and Q2 revenue guidance given with mixed signal — Management updated FY26 revenue to $720M–$760M (consensus ~$740M) and Q2 revenue to $170M–$185M (consensus ~$182M). The ranges include the consensus midpoint but Q2 guidance is slightly below street expectations, leaving guidance impact mixed. Q1 Report & Guidance
• Negative Sentiment: Market reaction to a new deal with SAB was tepid — Coverage noted the stock inched lower on a new SAB agreement, suggesting investors may be cautious about deal terms or near‑term dilution/earnings impact. This likely weighed on sentiment for some holders. SAB Deal Reaction

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. CANADA LIFE ASSURANCE Co purchased a new position in shares of Emergent Biosolutions during the 4th quarter worth $45,000. Legal & General Group Plc acquired a new stake in shares of Emergent Biosolutions during the 2nd quarter worth about $31,000. Raymond James Financial Inc. acquired a new stake in shares of Emergent Biosolutions during the 2nd quarter worth about $53,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Emergent Biosolutions during the 4th quarter worth about $107,000. Finally, Abel Hall LLC acquired a new stake in shares of Emergent Biosolutions during the 4th quarter worth about $129,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on EBS. Wall Street Zen lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. HC Wainwright decreased their price objective on Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Finally, Weiss Ratings lowered Emergent Biosolutions from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Emergent Biosolutions has an average rating of “Hold” and a consensus price target of $12.00.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.